Mark Pepys
Mark Pepys
Unknown affiliation
Verified email at
Cited by
Cited by
C-reactive protein: a critical update
MB Pepys, GM Hirschfield
The Journal of clinical investigation 111 (12), 1805-1812, 2003
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
J Danesh, JG Wheeler, GM Hirschfield, S Eda, G Eiriksdottir, A Rumley, ...
New England journal of medicine 350 (14), 1387-1397, 2004
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
G Liuzzo, LM Biasucci, JR Gallimore, RL Grillo, AG Rebuzzi, MB Pepys, ...
New England journal of medicine 331 (7), 417-424, 1994
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring …
W Koenig, M Sund, M Fröhlich, HG Fischer, H Löwel, A Döring, ...
Circulation 99 (2), 237-242, 1999
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
J Danesh, P Whincup, M Walker, L Lennon, A Thomson, P Appleby, ...
Bmj 321 (7255), 199-204, 2000
Common core structure of amyloid fibrils by synchrotron X-ray diffraction
M Sunde, LC Serpell, M Bartlam, PE Fraser, MB Pepys, CCF Blake
Journal of molecular biology 273 (3), 729-739, 1997
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
MB Pepys, ML Baltz
Advances in immunology 34, 141-212, 1983
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
DR Booth, M Sunde, V Bellotti, CV Robinson, WL Hutchinson, PE Fraser, ...
Nature 385 (6619), 787-793, 1997
The physiological structure of human C-reactive protein and its complex with phosphocholine
D Thompson, MB Pepys, SP Wood
Structure 7 (2), 169-177, 1999
C-reactive protein fifty years on
MB Pepys
The Lancet 317 (8221), 653-657, 1981
Association between C-reactive protein and features of the metabolic syndrome: a population-based study.
M Fröhlich, A Imhof, G Berg, WL Hutchinson, MB Pepys, H Boeing, ...
Diabetes care 23 (12), 1835-1839, 2000
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.
DM Vigushin, MB Pepys, PN Hawkins
The Journal of clinical investigation 91 (4), 1351-1357, 1993
Targeting C-reactive protein for the treatment of cardiovascular disease
MB Pepys, GM Hirschfield, GA Tennent, J Ruth Gallimore, MC Kahan, ...
Nature 440 (7088), 1217-1221, 2006
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis
HJ Lachmann, DR Booth, SE Booth, A Bybee, JA Gilbertson, JD Gillmore, ...
New England Journal of Medicine 346 (23), 1786-1791, 2002
Human lysozyme gene mutations cause hereditary systemic amyloidosis
MB Pepys, PN Hawkins, DR Booth, DM Vigushin, GA Tennent, AK Soutar, ...
Nature 362 (6420), 553-557, 1993
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction
M Griselli, J Herbert, WL Hutchinson, KM Taylor, M Sohail, T Krausz, ...
The Journal of experimental medicine 190 (12), 1733-1740, 1999
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein
JD Gillmore, LB Lovat, MR Persey, MB Pepys, PN Hawkins
The Lancet 358 (9275), 24-29, 2001
Effect of alcohol consumption on systemic markers of inflammation
A Imhof, M Froehlich, H Brenner, H Boeing, MB Pepys, W Koenig
The Lancet 357 (9258), 763-767, 2001
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
MCM Bickerstaff, M Botto, WL Hutchinson, J Herbert, GA Tennent, ...
Nature medicine 5 (6), 694-697, 1999
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
MB Pepys, J Herbert, WL Hutchinson, GA Tennent, HJ Lachmann, ...
Nature 417 (6886), 254-259, 2002
The system can't perform the operation now. Try again later.
Articles 1–20